Oculus Sees Expanded Label Claim for European Formulation of Dermacyn Wound Care
Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) a healthcare company that designs, produces and markets innovative, safe and effective anti-infective products and medical devices while also developing multiple drug candidates, today announced that a pending reclassification of the company's CE Mark for the European formulation Dermacyn(tm) Wound Care for the European market is expected by year's end. The reclassification is under the review of the British Standards Institution (BSI), which is the world's largest certification body, and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. Reclassified as a class III medical device, the newest indication would include 'possible local antimicrobial effect in the wound bed.'
'We are pleased with the expanded label indication as it will help increase sales for our existing sales partners in Europe and secondly, increases our chances of licensing our anti-infective drug product to prospective European partners focused on the surgical suite,' said Hoji Alimi, Oculus founder and CEO. 'As evidenced by our effective collaborative efforts with partners in the United States and Mexico, our partnership strategy has facilitated a sustainable rapid sales ramp while minimizing expenses since our partners underwrite the costs associated with marketing and sales.'
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.